Advances in biomarkers for esophageal cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92(3), 549–555 (2001).
   PubMed Web of Science ®Google Scholar
• Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review1975–2004. SEER Cancer Statistics Review 1975–2004 (2007).
   Google Scholar
• Thompson SK, Ruszkiewicz AR, Jamieson GG et al. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann. Surg. Oncol. 15(12), 3447–3458 (2008).
   PubMed Web of Science ®Google Scholar
• Walker RA, Bartlett JM, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 61(7), 818–824 (2008).
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Bilous M, Dowsett M et al. Emerging technologies for assessing HER2 amplification. Am. J. Clin. Pathol. 132(4), 539–548 (2009).
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Roda JM, Guenterberg KD et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol. Cancer. Ther. 8(11), 2983–2991 (2009).
   PubMed Web of Science ®Google Scholar
• Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. APMIS 117(10), 737–745 (2009).
   PubMed Web of Science ®Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27(34), 5838–5847 (2009).
   PubMed Web of Science ®Google Scholar
• Brien TP, Odze RD, Sheehan CE, Mckenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum. Pathol. 31(1), 35–39 (2000).
   PubMed Web of Science ®Google Scholar
• Reichelt U, Duesedau P, Tsourlakis M et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod. Pathol. 20(1), 120–129 (2007).
   PubMed Web of Science ®Google Scholar
• Langer R, Rauser S, Feith M et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod. Pathol. 24(7), 908–916 (2011).
   PubMed Web of Science ®Google Scholar
• Flejou JF, Paraf F, Muzeau F et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J. Clin. Pathol. 47(1), 23–26 (1994).
   PubMed Web of Science ®Google Scholar
• Hardwick RH, Barham CP, Ozua P et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur. J. Surg. Oncol. 23(1), 30–35 (1997).
   PubMed Web of Science ®Google Scholar
• Hu Y, Bandla S, Godfrey TE et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod. Pathol. 24(7), 899–907 (2011).
   PubMed Web of Science ®Google Scholar
• Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann. Surg. Oncol. 18(7), 2010–2017 (2011).
   PubMed Web of Science ®Google Scholar
• Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann. Surg. 221(6), 677–683 (1995).
   PubMed Web of Science ®Google Scholar
• Yoon HH, Shi Q, Sukov WR et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin. Cancer Res. 18(2), 546–554 (2012).
   PubMed Web of Science ®Google Scholar
• Birner P, Jesch B, Friedrich J et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann. Surg. Oncol. 18(12), 3330–3337 (2011).
   PubMed Web of Science ®Google Scholar
• Stoecklein NH, Hosch SB, Bezler M et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13(5), 441–453 (2008).
   PubMed Web of Science ®Google Scholar
• Friess H, Fukuda A, Tang WH et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J. Surg. 23(10), 1010–1018 (1999).
   PubMed Web of Science ®Google Scholar
• Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J. Gastrointest. Surg. 16(10), 1821–1829 (2012).
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Dreilich M, Wanders A, Brattstrom D et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis. Esophagus 19(4), 224–231 (2006).
   PubMed Web of Science ®Google Scholar
• Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int. J. Radiat Oncol. Biol. Phys. 57(5), 1323–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Uno M, Otsuki T, Kurebayashi J et al. Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int. J. Cancer 94(4), 474–479 (2001).
   PubMed Web of Science ®Google Scholar
• Safran H, Dipetrillo T, Akerman P et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 405–409 (2007).
   PubMed Web of Science ®Google Scholar
• Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J. Clin. Pathol. 58(4), 343–351 (2005).
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Kountouras J, Zavos C, Chatzopoulos D. New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J. Surg. Res. 125(2), 189–212 (2005).
   PubMed Web of Science ®Google Scholar
• Chung Y, Law S, Kwong DL, Luk JM. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Dis. Esophagus 24(1), 49–55 (2011).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 3, 4–10 (2005).
   Google Scholar
• Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin. Cancer Res. 11(4), 1434–1440 (2005).
   PubMed Web of Science ®Google Scholar
• Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br. J. Cancer 100(9), 1385–1392 (2009).
   PubMed Web of Science ®Google Scholar
• Zhan P, Wang J, Lv XJ et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J. Thorac. Oncol. 4(9), 1094–1103 (2009).
   PubMed Web of Science ®Google Scholar
• Liu P, Chen W, Zhu H et al. Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas. Jpn. J. Clin. Oncol. 39(10), 644–650 (2009).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ishiguro H, Kuwabara Y et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J. Exp. Clin. Cancer Res. 29(83), 1756–9966 (2010).
   Google Scholar
• Duhaylongsod FG, Wolfe WG. Barrett's esophagus and adenocarcinoma of the esophagus and gastroesophageal junction. J. Thorac. Cardiovasc. Surg. 102(1), 36–41; discussion 41–32 (1991).
   PubMed Web of Science ®Google Scholar
• Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, Van Blankenstein M, Tilanus HW. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut 33(11), 1454–1458 (1992).
   PubMed Web of Science ®Google Scholar
• Sabel MS, Pastore K, Toon H, Smith JL. Adenocarcinoma of the esophagus with and without Barrett mucosa. Arch. Surg. 135(7), 831–835; discussion 836 (2000).
   PubMedGoogle Scholar
• Portale G, Peters JH, Hagen JA et al. Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa. Arch. Surg. 140(6), 570–574; discussion 574–575 (2005).
   PubMedGoogle Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9), 1523–1529 (2008).
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16(2), 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J. Natl Cancer Inst. 101(19), 1306–1307 (2009).
   PubMedGoogle Scholar
• Wu CW, Chen GD, Fann CS et al. Clinical implications of chromosomal abnormalities in gastric adenocarcinomas. Genes Chromosomes Cancer 35(3), 219–231 (2002).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7(10), 2958–2970 (2001).
   PubMed Web of Science ®Google Scholar
• Jankowski J, Mcmenemin R, Hopwood D, Penston J, Wormsley KG. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin. Sci. (Lond.) 81(5), 663–668 (1991).
   PubMed Web of Science ®Google Scholar
• Jankowski J, Hopwood D, Wormsley KG. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. Scand. J. Gastroenterol. 27(2), 147–154 (1992).
   PubMed Web of Science ®Google Scholar
• Brito MJ, Filipe MI, Linehan J, Jankowski J. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. Int. J. Cancer 60(1), 27–32 (1995).
   PubMed Web of Science ®Google Scholar
• Wilkinson NW, Black JD, Roukhadze E et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J. Gastrointest. Surg. 8(4), 448–453 (2004).
   PubMed Web of Science ®Google Scholar
• Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod. Pathol. 10(2), 105–112 (1997).
   PubMed Web of Science ®Google Scholar
• Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer 54(2), 213–219 (1993).
   PubMed Web of Science ®Google Scholar
• Demicco EG, Farris AB 3rd, Baba Y et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod. Pathol. 24(9), 1177–1190 (2011).
   PubMed Web of Science ®Google Scholar
• Wang KL, Wu T-T, Choi IS et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas. Cancer 109(4), 658–667 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311–1318 (1995).
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120(4), 781–787 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Adelstein DJ, Rice TW et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J. Thorac. Oncol. 5(2), 229–235 (2010).
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol. 24(10), 1612–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Ferry DR, Anderson M, Beddard K et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin. Cancer Res. 13(19), 5869–5875 (2007).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548–2556 (2004).
   PubMed Web of Science ®Google Scholar
• Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV. Obesity and gastrointestinal cancer. Br. J. Surg. 97(5), 628–642 (2010).
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505–518 (2004).
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8(12), 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Lukanova A, Soderberg S, Stattin P et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 13(6), 509–516 (2002).
   PubMed Web of Science ®Google Scholar
• Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. USA 90(23), 11217–11221 (1993).
   PubMed Web of Science ®Google Scholar
• Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62(10), 2942–2950 (2002).
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68(24), 10238–10246 (2008).
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Sciacca L et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem. 114(1), 23–37 (2008).
   PubMedGoogle Scholar
• Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28(1), 20–47 (2007).
   PubMed Web of Science ®Google Scholar
• Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br. J. Surg. 97(7), 1020–1027 (2010).
   PubMed Web of Science ®Google Scholar
• Piao W, Wang Y, Adachi Y et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther. 7(6), 1483–1493 (2008).
   PubMed Web of Science ®Google Scholar
• Iravani S, Zhang HQ, Yuan ZQ et al. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of barrett’s neoplasia. Hum. Pathol. 34(10), 975–982 (2003).
   PubMed Web of Science ®Google Scholar
• Liu Y-C, Leu CM, Wong FH et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J. Biomed. Sci. 9(6), 665–674 (2002).
   PubMed Web of Science ®Google Scholar
• Doyle SL, Donohoe CL, Finn SP et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am. J. Gastroenterol. 107(2), 196–204 (2012).
   PubMed Web of Science ®Google Scholar
• Donohoe CL, Doyle SL, Mcgarrigle S et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br. J. Surg. 99(3), 387–396 (2012).
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14), 2126–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Russo J, Russo IH. Breast development, hormones and cancer. Adv. Exp. Med. Biol. 630, 52–56 (2008).
   PubMed Web of Science ®Google Scholar
• Chen JQ, Brown TR, Yager JD. Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria. Adv. Exp. Med. Biol. 630, 1–18 (2008).
   PubMed Web of Science ®Google Scholar
• Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66(1), 33–38 (2010).
   PubMed Web of Science ®Google Scholar
• Sharpe RM. The roles of oestrogen in the male. Trends Endocrinol. Metab. 9(9), 371–377 (1998).
   PubMed Web of Science ®Google Scholar
• Zuguchi M, Miki Y, Onodera Y et al. Estrogen receptor α and β in esophageal squamous cell carcinoma. Cancer Sci. 103(7), 1348–1355 (2012).
   PubMed Web of Science ®Google Scholar
• Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711), 580–584 (1998).
   PubMed Web of Science ®Google Scholar
• Hsu KF, Lin CK, Yu CP et al. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis. Esophagus 22(5), 402–408 (2009).
   PubMed Web of Science ®Google Scholar
• Dannenberg AJ, Altorki NK, Boyle JO et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2(9), 544–551 (2001).
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5), 705–716 (1998).
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 94(7), 3336–3340 (1997).
   PubMed Web of Science ®Google Scholar
• Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 33(7), 708–714 (2002).
   PubMed Web of Science ®Google Scholar
• Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 24(4), 2349–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57(7), 1276–1280 (1997).
   PubMed Web of Science ®Google Scholar
• Sheehan KM Sheahan K, O'Donoghue DP et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282(13), 1254–1257 (1999).
   PubMed Web of Science ®Google Scholar
• Yip-Schneider MT, Barnard DS, Billings SD et al. Cyclooxygenase-2expression in human pancreatic adenocarcinomas. Carcinogenesis 21(2), 139–146 (2000).
   PubMed Web of Science ®Google Scholar
• Shirahama T, Arima J-I, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92(1), 188–193 (2001).
   PubMed Web of Science ®Google Scholar
• Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58(17), 3761–3764 (1998).
   PubMed Web of Science ®Google Scholar
• Wang D, Dubois RN. Prostaglandins and cancer. Gut 55(1), 115–122 (2006).
   PubMed Web of Science ®Google Scholar
• Prins MJ, Verhage RJ, Ten Kate FJ, Van Hillegersberg R. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J. Gastrointest. Surg. 16(5), 956–966 (2012).
   PubMed Web of Science ®Google Scholar
• Takatori H, Natsugoe S, Okumura H et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur. J. Surg. Oncol. 34(4), 397–402 (2008).
   PubMed Web of Science ®Google Scholar
• Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124(1), 47–56 (2003).
   PubMed Web of Science ®Google Scholar
• Heath EI, Canto MI, Piantadosi S et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl Cancer Inst. 99(7), 545–557 (2007).
   PubMedGoogle Scholar
• Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis. Esophagus 18(3), 146–150 (2005).
   PubMed Web of Science ®Google Scholar
• Nakatsu T, Motoyama S, Maruyama K et al. Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg. Today 42(7), 652–658 (2012).
   PubMed Web of Science ®Google Scholar
• Shimada H, Nabeya Y, Okazumi S et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J. Surg. Oncol. 83(4), 248–252 (2003).
   PubMed Web of Science ®Google Scholar
• Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J. Gastroenterol. 12(23), 3746–3750 (2006).
   PubMed Web of Science ®Google Scholar
• Gubbay J, Collignon J, Koopman P et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 346(6281), 245–250 (1990).
   PubMed Web of Science ®Google Scholar
• Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr. Opin. Genet. Dev. 7(3), 338–344 (1997).
   PubMed Web of Science ®Google Scholar
• Sinclair AH, Berta P, Palmer MS et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 346(6281), 240–244 (1990).
   PubMed Web of Science ®Google Scholar
• Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 27(6), 1409–1420 (1999).
   PubMed Web of Science ®Google Scholar
• Ferrari S, Harley VR, Pontiggia A, Goodfellow PN, Lovell-Badge R, Bianchi ME. SRY, like HMG1, recognizes sharp angles in DNA. Embo J. 11(12), 4497–4506 (1992).
   PubMed Web of Science ®Google Scholar
• Weiss MA. Floppy SOX: mutual induced fit in hmg (high-mobility group) box-DNA recognition. Mol. Endocrinol. 15(3), 353–362 (2001).
   PubMedGoogle Scholar
• Boiani M, Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell. Biol. 6(11), 872–884 (2005).
   PubMed Web of Science ®Google Scholar
• Wang Q, He W, Lu C et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 29(4), 1233–1241 (2009).
   PubMed Web of Science ®Google Scholar
• Scholer HR, Ruppert S, Suzuki N, Chowdhury K, Gruss P. New type of POU domain in germ line-specific protein Oct-4. Nature 344(6265), 435–439 (1990).
   PubMed Web of Science ®Google Scholar
• Scholer HR. Octamania: the POU factors in murine development. Trends Genet. 7(10), 323–329 (1991).
   PubMed Web of Science ®Google Scholar
• Pesce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 19(4), 271–278 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou X, Huang GR, Hu P. Over-expression of Oct4 in human esophageal squamous cell carcinoma. Mol. Cells 32(1), 39–45 (2011).
   PubMed Web of Science ®Google Scholar
• He W, Li K, Wang F, Qin YR, Fan QX. Expression of OCT4 in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. World J. Gastroenterol. 18(7), 712–719 (2012).
   PubMed Web of Science ®Google Scholar
• Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 10(8), 590–601 (2005).
   PubMed Web of Science ®Google Scholar
• Sauter ER, Keller SM, Erner S, Goldberg M. HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. Cancer Lett. 75(1), 41–44 (1993).
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Hanawa M et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br. J. Cancer 92(7), 1253–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Polkowski W, Van Sandick JW, Offerhaus GJ et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. 6(3), 290–297 (1999).
   PubMed Web of Science ®Google Scholar
• Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 9(6), 1471–2407 (2009).
   Google Scholar
• Yamamoto Y, Yamai H, Seike J et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann. Surg. Oncol. 19(3), 757–765 (2012).
   PubMed Web of Science ®Google Scholar
• Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int. J. Oncol. 31(3), 493–499 (2007).
   PubMed Web of Science ®Google Scholar
• Sano A, Kato H, Sakurai S et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 16(2), 506–514 (2009).
   PubMed Web of Science ®Google Scholar
• Nakamura H, Saji H, Ogata A et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer 103(1), 61–66 (2003).
   PubMed Web of Science ®Google Scholar
• Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med. Oncol. 29(2), 933–940 (2012).
   PubMed Web of Science ®Google Scholar
• Bizari L, Borim AA, Leite KR et al. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet. Cytogenet. 165(1), 41–50 (2006).
   PubMedGoogle Scholar
• Schoppmann SF, Jesch B, Zacherl J et al. HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. Br. J. Surg. 98(10), 1408–1413 (2011).
   PubMed Web of Science ®Google Scholar
• Lagarde SM, Ten Kate FJW, Richel DJ, Offerhaus GJA, Van Lanschot JJB. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. 14(2), 977–991 (2007).
   PubMed Web of Science ®Google Scholar